Latham Guides Genstar In $400M Pharma Research Co. Buy
Having inked a definitive agreement and gotten support from the company's board of directors, Genstar plans to purchase the global research firm for $8 per share in an all-cash deal, according to ERT. The purchase price represents a premium of about 38 percent over the company's average closing price for the last three months and...

